RheumNow Week in Review – 14 October 2015 Save

Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:

1. Prevalence of noninfectious uveitis in USA: Nearly 300,000 adults and 22,000 children in 2015 (based on claims data). http://buff.ly/2e7ew4y
2. Global biosimilars sales = 3.5 billion in 2015; poised to reach $15.6 billion by 2022. https://t.co/TATv2rgYTM
3. Patients with VERY high levels of CRP & nonspecific findings should raise suspicion for other non-rheumatic diagnoses (infection, malignancy). https://t.co/xbCTGXPd5L
4. Medicare study shows no increased risk of breast cancer in RA or IBD women taking MTX, 6MP or TNF inhibitors! https://t.co/lHyUbyjNCQ
5. Norwegian HUNT study shows no increased risk of fracture among 2804 self reported psoriasis patients. https://t.co/PHNMUac27A
6. High ESR/CRP in a Rheumatology Hospital: Rheumatic diseases were most common (52%); lead by PMR (38%), seronegative RA, infection (25%), neoplasia (9%). https://t.co/9mkJhQMXwZd
7. Diabetes has frequent articular and periarticular findings: including OA knee (most common at 49%), carpal tunnel syndrome (29%), frozen shoulder (23%), cheiroarthropathy (16%). https://t.co/pGRNI6wQTQ
8. Metanalysis: ankle replacement (TAA) vs arthrodeisis w/ similar outcomes but more reoperations, complications w/ TAA. https://t.co/dGbZLl28mi
9. Phase II ACCLAIM small trial fails to show significant benefit/safety of Abatacept in multiple sclerosis (42 pts). https://t.co/GeU5XnhePt
10. Endocannabinoid, Resunab (JBT-101), in a clinical trial for scleroderma. It decreases TGF-B & collagen. https://t.co/Iu8OLPm5BC
11. Mayo study of incident Sarcoidosis shows 3 fold higher risk of venous thrombosis & 4 fold risk of pulm embolism. https://t.co/C4gZc951aJ
12. My Take on New Ocular Screening Guidelines for Plaquenil 
13. 1/3 of First Degree Relatives to AS patients are at Risk of Spondyloarthritis
14. New Criteria for the Cryopyrinopathies (CAPS)
15. Long-Term Outcomes of Aromatase Inhibitor Arthralgias